Cargando…

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

BACKGROUND: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. METHODS: Pretreated non-squamous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landi, Lorenza, D’Incà, Federica, Gelibter, Alain, Chiari, Rita, Grossi, Francesco, Delmonte, Angelo, Passaro, Antonio, Signorelli, Diego, Gelsomino, Francesco, Galetta, Domenico, Giannarelli, Diana, Soto Parra, Hector, Minuti, Gabriele, Tiseo, Marcello, Migliorino, Maria Rita, Cognetti, Francesco, Toschi, Luca, Bidoli, Paolo, Piantedosi, Francovito, Calabro’, Luana, Cappuzzo, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868703/ https://www.ncbi.nlm.nih.gov/pubmed/31752994 http://dx.doi.org/10.1186/s40425-019-0793-8

Ejemplares similares

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
por: Passiglia, Francesco, et al.
Publicado: (2018)

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
por: Vecchiarelli, Silvia, et al.
Publicado: (2018)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
por: Landi, Lorenza, et al.
Publicado: (2020)

Pretreated EGFR(del19)/BRAF(V600E) Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report
por: Orciuolo, Corrado, et al.
Publicado: (2023)

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
por: Ceddia, Serena, et al.
Publicado: (2022)

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
por: Passaro, Antonio, et al.
Publicado: (2021)

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
por: Esposito Abate, Riziero, et al.
Publicado: (2019)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
por: Cortellini, Alessio, et al.
Publicado: (2020)

Targeting targeted agents: open issues for clinical trial design
por: Bria, Emilio, et al.
Publicado: (2009)

Measuring disease activity in Crohn’s disease: what is currently available to the clinician
por: D’Incà, Renata, et al.
Publicado: (2014)

Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut
por: Michielan, Andrea, et al.
Publicado: (2015)

Biomarkers in IBD: What to Utilize for the Diagnosis?
por: D’Incà, Renata, et al.
Publicado: (2023)

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
por: Cortellini, Alessio, et al.
Publicado: (2021)

Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy
por: Banna, Giuseppe L., et al.
Publicado: (2021)

Exosomes: Tiny Clues for Mast Cell Communication
por: D’Incà, Federica, et al.
Publicado: (2015)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
por: Gridelli, Cesare, et al.
Publicado: (2023)

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients
por: Ferraresi, Virginia, et al.
Publicado: (2010)

Set up and programming of an ALICE Time-Of-Flight trigger facility and software implementation for its Quality Assurance (QA) during LHC Run 2
por: Toschi, Francesco
Publicado: (2016)

The clinician’s perspective on the 21-gene assay in early breast cancer
por: Cognetti, Francesco, et al.
Publicado: (2021)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Alternatives to Antibiotics to Prevent Necrotic Enteritis in Broiler Chickens: A Microbiologist's Perspective
por: Caly, Delphine L., et al.
Publicado: (2015)

Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Accuracy of lung cancer ICD-9-CM codes in Umbria, Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study
por: Montedori, Alessandro, et al.
Publicado: (2018)

Structural Health Monitoring Based on Acoustic Emissions: Validation on a Prestressed Concrete Bridge Tested to Failure
por: Tonelli, Daniel, et al.
Publicado: (2020)

Neurogenic Fever after Subarachnoid Hemorrhage in Animal Models: A Systematic Review
por: Migliorino, Ernesto, et al.
Publicado: (2023)

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
por: Cortellini, Alessio, et al.
Publicado: (2022)

The Biotin–Avidin Interaction in Biotinylated Gold Nanoparticles and the Modulation of Their Aggregation
por: Lyu, Yanchao, et al.
Publicado: (2021)

DNA-free genome editing in grapevine using CRISPR/Cas9 ribonucleoprotein complexes followed by protoplast regeneration
por: Najafi, Samaneh, et al.
Publicado: (2022)

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2021)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

The protective side of progesterone
por: Ferretti, Gianluigi, et al.
Publicado: (2007)

Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study
por: Bironzo, Paolo, et al.
Publicado: (2022)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_glftamsl740q71tf6t0ok9l7mh